### PATENT ASSIGNMENT COVER SHEET

# Electronic Version v1.1 Stylesheet Version v1.2

### EPAS ID: PAT2711029

| SUBMISSION TYPE:  |   |  | NEW ASSIGNMENT  |                |
|---|---|--|---|----------------|
| NATURE OF CONVEYANCE:   |   |  | ASSIGNMENT  |                |
| CONVEYING PARTY   | DATA  | 1  |   |                |
|   |   | Nar  | me  | Execution Date |
| DAVID MICHAEL GOLDSTEIN   |   |  |   | 11/21/2013     |
| KENNETH ALBERT  | BRAMELD   |  |   | 11/21/2013     |
| RECEIVING PARTY [   | ATA   |  |   |                |
| Name:   |   | IOPHAR   | MA, INC.  | ]              |
| Street Address:   |   |  | URT, SUITE 302  |                |
| City:   |   | SOUTH SAN FRANCISCO  |   |                |
| State/Country:  |   | ۱  |   |                |
| Postal Code:  | 94080   |  |   |                |
| Property T  | уре   |  | Number  |                |
| Property T  | vpe   |  | Number  | ]              |
| Property T<br>Application Number:   |   | 1411792  |   |                |
|   |   | 1411792  |   |                |
| Application Number:   | E DATA  | 1411792  | 27  |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:  | E DATA<br>(202)<br>2024   | 9408-440<br>1084000  | 27  |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:  | E DATA<br>(202)<br>2024<br>nanc   | 2)408-440<br>4084000<br>cy.foster@   | 27<br>00<br>@finnegan.com   |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:<br><i>Correspondence will I</i>  | E DATA<br>(202)<br>2024<br>nanc<br>be sent via US                             | 9408-440<br>4084000<br>cy.foster@<br><i>Mail whe</i>                                   | 27<br>00<br>@finnegan.com<br><i>en the email attempt is unsuccessful.</i>   |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:  | E DATA<br>(202)<br>2024<br>nanc<br>be sent via US i<br>: PRIN                 | 2)408-440<br>4084000<br>cy.foster((<br><i>Mail whe</i><br>NCIPIA E                     | 27<br>00<br>@finnegan.com   |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:<br><i>Correspondence will I</i><br>Correspondent Name  | E DATA<br>(202)<br>2024<br>nanc<br><i>be sent via US J</i><br>: PRIN<br>901 I | 0)408-440<br>4084000<br>cy.foster((<br><i>Mail whe</i><br>NCIPIA E<br>NEW YC           | 27<br>@finnegan.com<br><i>en the email attempt is unsuccessful.</i><br>BIOPHARMA/FINNEGAN   |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:<br><i>Correspondence will I</i><br>Correspondent Name<br>Address Line 1:                                       | E DATA<br>(202)<br>2024<br>nanc<br>be sent via US J<br>: PRIN<br>901 I<br>WAS | 2)408-440<br>4084000<br>cy.foster(<br><i>Mail whe</i><br>NCIPIA E<br>NEW YC<br>SHINGTC | 27<br>@finnegan.com<br><i>en the email attempt is unsuccessful.</i><br>BIOPHARMA/FINNEGAN<br>DRK AVE., NW   |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:<br><i>Correspondence will I</i><br>Correspondent Name<br>Address Line 1:<br>Address Line 4:                    | E DATA<br>(202)<br>2024<br>nanc<br>be sent via US<br>: PRIN<br>901 I<br>WAS   | )408-440<br>1084000<br>cy.foster(<br><i>Mail whe</i><br>NCIPIA E<br>NEW YC<br>SHINGTC  | 27<br>@finnegan.com<br><i>en the email attempt is unsuccessful.</i><br>BIOPHARMA/FINNEGAN<br>ORK AVE., NW<br>DN, DISTRICT OF COLUMBIA 20001                     |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:<br><i>Correspondence will I</i><br>Correspondent Name<br>Address Line 1:<br>Address Line 4:                    | E DATA<br>(202)<br>2024<br>nanc<br>be sent via US<br>: PRIN<br>901 I<br>WAS   | a)408-440<br>4084000<br>cy.foster(<br><i>Mail whe</i><br>NCIPIA E<br>NEW YC<br>SHINGTO | 27<br>@finnegan.com<br><i>en the email attempt is unsuccessful.</i><br>BIOPHARMA/FINNEGAN<br>DRK AVE., NW<br>DN, DISTRICT OF COLUMBIA 20001<br>11913.1001-00000 |                |
| Application Number:<br>CORRESPONDENCE<br>Fax Number:<br>Phone:<br>Email:<br><i>Correspondence will I</i><br>Correspondent Name<br>Address Line 1:<br>Address Line 4:<br>ATTORNEY DOCKET | E DATA<br>(202)<br>2024<br>nanc<br>be sent via US<br>: PRIN<br>901 I<br>WAS   | )408-440<br>4084000<br>cy.foster(<br><i>Mail whe</i><br>NCIPIA E<br>NEW YC<br>SHINGTC  | 27<br>27<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20<br>20  |                |

Total Attachments: 4 source=Assign-Declaration#page1.tif source=Assign-Declaration#page2.tif source=Assign-Declaration#page3.tif source=Assign-Declaration#page4.tif

### ASSIGNMENT AND DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION

WHEREAS I/We, the below named inventor(s), (hereinafter referred to as Assignor(s)), of a claimed invention in a PCT International Application entitled:

#### PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS filed on 16 May 2012 as PCT International Application No. PCT/US2012/038135.

| WHEREAS,      | PRINCIPIA BIOPHARMA INC. |
|---------------|--------------------------|
| a corporation | of Delaware, USA         |

whose post office address is 400 East Jamie Court, Suite 302, So. San Francisco, California 94080, USA

(hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, provisional Application No. 61/486,933 filed 17 May 2011, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority in any foreign country on the basis of the above provisional application (if any), as well as all rights to claim priority on the basis of this application in any foreign country, and all applications for Letters Patent which may hereafter be filed for this invention in any foreign country and all Letters Patent which may be granted on this invention in any foreign country, and all extensions, renewals, and reissues thereof; and I/We hereby authorize and request the Director of the United States Patent and Trademark Office and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

As a named inventor below, I hereby declare that: (1) This declaration is directed to the above-identified application; (2) the above-identified application was made or authorized to be made by me; (3) my residence and mailing address are as stated below next to my name; and (4) I believe I am an original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statements made in this declaration are punishable by fine or imprisonment of not more than five (5) years, or both, under section 1001 of Title 18 of the United States Code.

As a below named inventor. I have reviewed and understand the contents of the application, including the claims, and am aware of the duty to disclose to the US PTO all information known to me to be material to patentability as defined in 37C.F.R. § 1.56.

## Authorization To Permit Access To Application by Participating Offices:

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified patent application is filed access to the above-'KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent application is filed to have access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the Applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified application is filed to have access to the above identified patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respect to: 1) the aboveidentified patent application-as-filed; 2) any foreign application to which the above-identified patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices.

I hereby appoint the patent practitioners associated with **Principia Biopharma/Finnegan, CUSTOMER NUMBER** 117160 to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

IN TESTIMONY WHEREOF, I/We have hereunto set our hands.

| County of State of    | California Acknowledgment  | Name:<br>Address:<br>By:<br>Date: | David Michael GOLDSTEIN<br>122 Danbury Lane<br>Redwood Gity, California,94061, USA |
|-----------------------|--|-----------------------------------|--|
| Subscribed            | and sworn to before me this day of   | , 20                              | -  |
|                       | , Notary Public  |                                   |  |
| County of<br>State of | **Please See Attach** ss.<br>—— California Acknowledgment<br>—— California Jurat | Name:<br>Address:<br>By:          | Kenneth Albert BRAMELD<br>345 Camino Al Lago<br>Menio Park, California 94027, USA  |
| Subscribed            | and sworn to before me this day of   | Date:                             | - May 24, 2013   |

| State of California  | •  |
|--|--|
| County of San mater  | <b>8.8.</b>  |
| -  |  |
| Subscribed and sworn to (or affirmed) before me on t   | his <u> </u>   |
| 20.13, by Kenneth Albert   | <u>Brameld</u> en  |
| hiame ca signa   | * (1)  |
| Savid Michael GoldsTein<br>Harrord Sogner 121  | , proved to me on the basis of   |
| satisfactory evidence to be the person(s) who appear   | nad hadora ma  |
| sensieurit auroure m ne nie heisou(s) aur shhae  |  |
| and the second | P. FAKERI  |
|  | COMM. #2003459 Z   |
|  | San Mateo County<br>My Comm. Expires Feb. 6, 2017  |
| Signature of Notary Public.  | and the second |
| For other required information frietery learns, Commission Net, sic.)  | •  |
| OPTIONAL INFORMA   | Səzi<br>Tiom   |
| Although the information in this section is not required by law, it could  | d prevent fraudulent removel and realtachment of   |
| this jurat to an unauthorized document and may prove useful to pera  | Che reiying on the alleoned document.  |
| Description of Attached Document   | Method of Affient Identification   |
| The certificate is attached to a document titled/for the purpose of  |  |
| ASSIGNMENT & Declastion  | C terminia) of identification () credible withers(es)  |
| s  | Notarial event is detailed in notary journal on:   |
| & power of Attorney For  | <ul> <li>Cardoona rodo dodudor no tob dodudente pet 4 devoluti &amp; Thrank rows, much.</li> </ul>               |
| & power of Attorney For  | Bears at Heriter a   |
| Assignment & Declarion<br>& power of Attorney For<br>while, or design patent                                     | Paga # Entry #   |
| AMUCACION.   | Page # Entry #<br>Notary contact   |
| & power of Attorney For<br>WTILITY or Design paters<br>ANNICATION.<br>Containing 4 pages, and dated 11/21/17     | Notary contact   |
| AMUCACION.   | Notary contact   |
| AMUCACION.   | Notary contact   |
| AMUCACION.   | Notary contact   |

© 2010 Notary Learning Center - All Rights Reserved

.

.

1. 1

PATENT REEL: 032125 FRAME: 0018

.

SOLE/JOINT INVENTION (Worldwide Rights) Attorney Docket No. 11913-1001

| Assignee Name:   | PRINCIPIA BIOPHARMA INC. |
|------------------|--------------------------|
| Signature:       | Ulla SQU                 |
| Printed Name:    | Martin Rables            |
| Corporate Title: | CEO                      |
| Date:            | Nov. 14, 2013            |

Page 3 of 3

**RECORDED: 02/03/2014**